SCOTTSDALE, Ariz., April 22 Regenesis Biomedical, Inc., amedical technology company that markets the Provant(R) Wound Therapy System,announced today that the Symposium on Advanced Wound Care (SAWC) will presentits top Laboratory Research award to Regenesis. John Moffett, PhD, amolecular biologist, will be accepting the award on behalf of Regenesis.According to Michael McGovern, Abstract Coordinator for SAWC, "This year, SAWCis giving awards for the top scoring abstracts in each of four categories(Case Study, Clinical Research, Informational/Educational Report, andLaboratory Research)." The abstract, entitled "Increased gene expression incultured human dermal fibroblasts in response to a pulsed radio frequencyelectromagnetic field and implications in chronic wounds," received thehighest score in the Laboratory Research category. Dr. Moffett will acceptthe award at the SAWC annual meeting in San Diego, California, on April 25,2008.
Provant delivers cell proliferation induction(R) (CPI(R)) therapy based onRegenesis' proprietary pulsed radio frequency energy (PRFE) core technologyplatform. PRFE uses an optimized radiofrequency signal to stimulate dormantcells, causing them to replicate and to produce natural growth factors andother gene expression products, which facilitate reduction of the pain andedema associated with post-operative wound healing in soft tissues. Webelieve Provant is effective, economical, and easy-to-use.
In addition to the top science award from SAWC, Richard Isenberg, M.D.,Vice President of Clinical and Regulatory Affairs, will present a paperentitled "Pulsed Radio Frequency Energy Therapy in Elderly Patients with StageIII and IV Pressure Ulcers in Long-Term Care Settings" on Saturday, April 25,2008.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology companyfocused on noninvasive regenerative medicine products. Regenesis developed,patented, and now markets the Provant Wound Therapy System. Our customersinclude health care facilities and providers that serve patients with woundsbeing treated by acute care hospitals, long-term acute care hospitals, skillednursing facilities, rehabilitation centers, home health care agencies, andwound care clinics.Contact: Regenesis Biomedical, Inc. Media: Scott Robey, VP Marketing firstname.lastname@example.org Clinicians: Rick Isenberg, MD, VP Clinical Affairs email@example.com http://www.regenesisbiomedical.com
SOURCE Regenesis Biomedical, Inc.